Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
Amanda E.D. Van Swearingen(Duke Cancer Institute), Carey K. Anders(Duke University), C. Ryan Miller(University of North Carolina at Chapel Hill), Brian T. Golitz(University of North Carolina at Chapel Hill), Gary L. Johnson(University of Colorado Hospital), Robert S. McNeill(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Louisa A. Mounsey(Massachusetts General Hospital), Naim U. Rashid(Dana-Farber Cancer Institute), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Xin Chen(Qingdao University), Maria J. Sambade(University of North Carolina at Chapel Hill), Charlene Santos(University of North Carolina at Chapel Hill), Marni B. Siegel(University of North Carolina at Chapel Hill), Samantha M. Bevill(Broad Institute), Shivani Sud(University of North Carolina at Chapel Hill), Ryan Bash(University of North Carolina at Chapel Hill)
Cited by 42
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k